^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    etevritamab (AMG 596)

    i
    Other names: AMG 596, AMG-596
    Associations

    News

    Trials
    Company:
    Amgen
    Drug class:
    CD3 agonist, EGFRvIII inhibitor
    Related drugs:
    Associations

    News

    Trials
    26d
    Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma (clinicaltrials.gov)
    P1, N=30, Terminated, Amgen | Completed --> Terminated; Amgen business decision
    Trial termination • Combination therapy
    |
    etevritamab (AMG 596) • zeluvalimab (AMG 404)
    5years
    AMG 596, a novel anti-EGFRvIII bispecific T cell engager (BiTE®) molecule for the treatment of glioblastoma (GBM): planned interim analysis in recurrent GBM (rGBM) (SNO 2019)
    Enrollment is ongoing and additional data will be presented. NCT03296696.
    Late-breaking abstract
    |
    EGFR (Epidermal growth factor receptor)
    |
    etevritamab (AMG 596)